IRON Disc Medicine, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1816736 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-34.2%
TTM EPS YoY-18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.3%
ROA-36.6%
ROIC (approx.)-40.5%
Asset turnover—
Leverage & solvency
Liabilities / assets13.6%
Debt / equity0.10x
Current ratio20.30x
Interest coverage-61.10x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $170.64M | $96.67M | $69.26M | $33.44M | $25.17M |
| SG&A expense | $65.38M | $33.05M | $21.86M | $14.04M | $5.76M |
| Operating income | -$236.02M | -$129.72M | -$91.12M | -$47.48M | -$30.93M |
| Interest expense | $3.61M | $572,000 | $0 | — | $2.16M |
| Pretax income | -$211.82M | -$109.00M | -$76.33M | -$46.83M | — |
| Income tax | $361,000 | $355,000 | $99,000 | $0 | — |
| Net income | -$212.18M | -$109.36M | -$76.43M | -$46.83M | -$35.97M |
| EBITDA | -$235.74M | -$129.56M | -$91.03M | -$47.39M | -$30.90M |
| EPS (basic) | -6.01 | -3.96 | -3.42 | -45.05 | -40.95 |
| EPS (diluted) | -6.01 | -3.96 | -3.42 | -45.05 | -40.95 |
| Weighted avg. shares (diluted) | 35.30M | 27.61M | 22.32M | 1.04M | 878,407 |
| Balance sheet | |||||
| Cash & equivalents | $91.14M | $192.67M | $360.62M | $194.79M | $88.21M |
| Short-term investments | $700.01M | $297.45M | $0 | — | — |
| Current assets | $803.90M | $493.62M | $365.66M | $198.49M | $90.48M |
| PP&E, net | $1.16M | $751,000 | $170,000 | $168,000 | $106,000 |
| Total assets | $806.88M | $496.77M | $368.00M | $200.21M | $92.41M |
| Current liabilities | $36.64M | $23.32M | $21.44M | $22.58M | $13.42M |
| Long-term debt | $29.16M | $28.32M | $0 | — | — |
| Total debt | $29.16M | $28.32M | $0 | — | — |
| Total liabilities | $67.05M | $53.19M | $22.88M | $23.61M | $14.76M |
| Shareholders' equity | $739.83M | $443.59M | $345.12M | $176.60M | -$64.20M |
| Net debt | -$61.99M | -$164.35M | -$360.62M | — | — |
| Shares outstanding | 37.89M | 29.87M | 24.36M | 17.40M | 909,418 |
| Cash flow statement | |||||
| Operating cash flow | -$180.39M | -$93.93M | -$73.46M | -$42.25M | -$27.53M |
| Capital expenditure | $933,000 | $505,000 | $89,000 | $151,000 | $68,000 |
| Free cash flow | -$181.33M | -$94.43M | -$73.55M | -$42.40M | -$27.60M |
| Investing cash flow | -$394.30M | -$292.33M | -$89,000 | -$151,000 | -$68,000 |
| Financing cash flow | $473.41M | $218.31M | $239.38M | $148.98M | $89.93M |
| Depreciation & amortization | $281,000 | $156,000 | $100,000 | $89,000 | $32,000 |
| Stock-based compensation | $34.34M | $16.82M | $5.53M | $2.09M | $507,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.